All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

September 6th 2024

Liso-cel produced responses across subgroups of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL

September 6th 2024

Treatment with valemetostat demonstrated activity and was tolerable in patients with relapsed/refractory peripheral T-cell lymphoma.

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

September 6th 2024

D-VRd improved rates of MRD negativity and sustained MRD negativity vs VRd in transplant-eligible, newly diagnosed multiple myeloma.

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology

September 6th 2024

The NCCN Clinical Practice Guidelines in Oncology now list denileukin diftitox as an appropriate option for patients with cutaneous T-cell lymphoma.

New Research Offers Hope for Safer and More Effective Blood Stem Cell Transplants

September 6th 2024

Systematic identification of minor histocompatibility antigens informs outcomes after allogeneic stem cell transplantation.

Improved OS, Cost Effectiveness Are Necessary to Shift Later-Line TKIs to Frontline CML-CP

September 6th 2024

Elias Jabbour, MD, discusses the potential activity and financial benefit of novel and emerging TKIs for first-line management of chronic phase CML.

FDA Approves Bortezomib Injectable for Multiple Myeloma and MCL

September 6th 2024

The FDA has approved a new presentation of bortezomib for subcutaneous or intravenous administration.

Vorasidenib Breaks Through as the First Systemic Therapy for Select Patients With Glioma

September 6th 2024

Seema Nagpal, MD, discusses the significance of the FDA approval of vorasidenib for adult and pediatric patients with IDH1/2-mutant glioma.

Talazoparib Plus Pacritinib Aims to Improve the Limitations of Second-Line Therapy in MPNs

September 5th 2024

Peter Abdelmessieh, DO, MSC, discusses the phase 1 trial testing the combination of talazoparib and pacritinib in myeloproliferative neoplasms.

FDA Awards Orphan Drug Designation to ABD-147 for Neuroendocrine Carcinoma

September 5th 2024

ABD-147 has received orphan drug designation from the FDA for use in patients with neuroendocrine carcinoma.

Pyrotinib Plus Metronomic Vinorelbine Is Active in HER2+ Advanced Breast Cancer After Trastuzumab

September 5th 2024

Pyrotinib paired with metronomic vinorelbine was safe and displayed efficacy in HER2-positive advanced breast cancer after prior trastuzumab.

Immunotherapy Could Represent New Treatment Avenue in T-Cell Lymphoma

September 5th 2024

The investigation of treatments harnessing the immune system in patients with T-cell lymphoma could lead to "a new era" of therapy for this patient population.

Fox Chase Cancer Center Welcomes Dr Leah Grandi Holben

September 5th 2024

Leah Grandi Holben, MD, joined Fox Chase Cancer Center as an assistant professor in the General Hematology/Oncology Program.

FDA Grants Fast Track Designation to VMT01 for Unresectable/Metastatic MC1R+ Melanoma

September 5th 2024

The FDA has granted fast track designation to the MCR1-targeted theranostic ligand VMT01 for unresectable or metastatic melanoma.

FDA Grants Orphan Drug Designation to Certepetide in Cholangiocarcinoma

September 5th 2024

Certepetide has been granted orphan drug designation by the FDA for the treatment of patients with cholangiocarcinoma.

Medicare Drug Price Negotiation Program Will Result in Financial Burdens for Community Oncology Practices

September 5th 2024

Debra Patt, MD, PhD, MBA, FASCO, highlights considerations with financial burdens that will be placed on community providers and oncology practices.

Novel Cell-Free DNA Assays Expand the Reach of MRD Detection in Lymphoma

September 5th 2024

Reid W. Merryman, MD, discusses notable advancements with minimal residual disease assays in lymphoma.

The Treatment of Rare Tenosynovial Giant Cell Tumors Is Poised to Shift

September 5th 2024

R. Lor Randall, MD, FACS, details how he treats patients with TGCTs and the potential of vimseltinib to join pexidartinib in the treatment landscape.

Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL

September 4th 2024

Tisagenlecleucel is moving to earlier lines of therapy for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Novel Targets, Classes of Agents Could Refine Checkpoint Inhibition in NSCLC

September 4th 2024

Solange Peters, MD, PhD, discusses ways to refine checkpoint inhibition in the treatment of non–small cell lung cancer.